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ABSTRACT 
 
 
The possible impact of hydrophobic lectin nanoparticles on the prognosis and progression of 
Alzheimer's disease (AD) and cancers was investigated by Visual Molecular Dynamics (VMD) 
computer modeling programs available from the Beckmann Advanced Research Institute at 
the University of Illinois at Urbana. Our results indicate the possibility of impeding 
pathological aggregation of certain proteins such as modified tau- or beta-amyloid that are 
currently being considered as possible causes of Alzheimer's disease. VMD programs serve 
as useful tools for investigation hydrophobic protein aggregation that may play a role in 
aging of human populations. 
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1. INTRODUCTION 
  
      Visual Molecular Dynamics (VMD) computer modeling is a readily available, intuitive and 
powerful tool for studying complex molecular interactions such as protein aggregation and its 
effect on protein activity and physiological functions. We are reporting the first VMD 
investigation of the aggregation process of selected proteins, such as hydrophobic lectin 
nanoparticles, with potentially important applications in Nanomedicine for the prognosis and 
possibly therapy as well of cancers and Alzheimer’s Disease (AD). In the case of AD there is a 
large body of accumulated evidence that hydrophobic aggregation of modified proteins such as 
the (or  tau-)  and  beta-amyloid (or a-) abeta proteins may actually be the cause of AD. Any 
attempt at treatment of AD is however impeded by a lack of understanding of the highly complex 
interactions involved in the initiation and progression of AD, although- in the very rare cases of 
AD with a hereditary component- progress has been made through detailed genetic population 
models aided by computer statistical analysis. VMD has not been employed so far to unravel the 
very difficult complexity problems posed by the aggregation of hydrophobic proteins. As 
discussed in this report, the lectin plant proteins present both a useful model for studying 
hydrophobic nanoparticle aggregation and a possible approach to improving the prognosis and 
outcomes of AD as well as certain types of cancers not yet investigated through clinical trials. 
Therefore, VMD applications in Nanomedicine have the potential for aiding the design and 
implementation of successful clinical trials in cancer and AD.  
  
2.  LECTIN APPLICATIONS TO CANCER DETECTION AND TREATMENT 
Lectins are proteins, or more precisely glycoproteins, that agglutinate erythrocytes of some or 
all blood groups in vitro (Sharon 1998). They are an important group of bioactive proteins and 
glycoproteins found in most organisms (Baianu and Prisecaru, 2011), including plants, 
vertebrates, invertebrates, bacteria and viruses, and have several important applications to the 
fields of health food and medical biotechnology. Lectins are used as tools in the fields of 
biochemistry, cell biology and immunology, as well as for diagnostic and therapeutic purposes in 
cancer research (Sharon and Lis 2002). Lectin aggregation can be employed on a large-scale 
basis for the commercial production of biologically active proteins (Takamatsu et al, 1999). 
Lectins have been used in glycoprotein purification, oligosaccharide analysis, as well as in cell-
selection processes. Lectins can bind reversibly with free sugars or with sugar residues of 
polysaccharides, glycoproteins or glycolipids (Goldstein and Poretz, 1986). There has been 
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increasing demand for novel diagnostic and medical cancer therapies that utilize non-traditional 
sources. Epidemiological studies indicate that the consumption of a plant-based diet is strongly 
associated with a reduced risk of developing several types of cancer (Block et al, 1992). Plants 
contain numerous phytochemicals that can alter cancer-associated biochemical pathways. One 
such group that was investigated examined for its role in cancer chemoprevention is lectins. 
Lectins were reported to bind preferentially to cancer cell membranes, or their receptors, causing 
cytotoxicity, apoptosis and/or tumor growth inhibition. Lectins were thought to become 
internalized into cells, and some lectins were claimed to cause cancer cell agglutination and/or 
aggregation. Present in common foods, some lectins resist acid and/or enzymatic digestion and 
also were reported to enter the bloodstream in an intact, and biologically active, form. Lectins 
possess a spectrum of beneficial, as well as harmful, effects both in vitro and in vivo. Ingestion of 
lectins also sequesters the available body pool of polyamines, thereby claimed to thwart cancer 
cell growth. They have also been reported to affect the immune system by altering the production 
of various interleukins, or by activating certain protein kinases. Lectins were also reported to bind 
to ribosomes and thus inhibit protein synthesis. Lectins may also modify the cell cycle by 
inducing non-apoptotic G1-phase accumulation mechanisms, G2 /M phase cell cycle arrest, and 
apoptosis, and might activate the caspase cascade. Lectins were also reported to down-regulate 
telomerase activity and inhibit angiogenesis. Lectins could inhibit cell adhesion, proliferation, 
colony formation and hemagglutination, and were reported to have cytotoxic effects on human 
tumor cells. Lectins could function as surface markers for tumor cell recognition, cell adhesion, 
signal transduction across the membrane, mitogenic cytotoxicity and apoptosis. Also, lectins 
were reported to modulate the growth, proliferation and apoptosis of premalignant and malignant 
cells both in vitro and in vivo.  
 
For many years, lectins have been considered to be toxic substances to both cells and animals, 
mainly because of the observed agglutination of erythrocytes and other cells in vitro. On the other 
hand, it has also been reported that lectins have an inhibitory effect on the growth of tumors. 
Their potential for clinical applications has been investigated only in recent years. Lectins are 
now being considered for use both in the diagnostics and therapeutics of cancers. Thus, lectins 
are quite versatile biomarkers and have been utilized in a variety of studies involving 
histochemical, biochemical and functional techniques for cancer cell characterization (Munoz et 
al, 2001). Lectins may also be very useful tools for the identification of cancers and the degree of 
metastasis, or cancer development stage.  Recently, there has been a tendency to shift lectins use 
from cancer detection to actual use in combating cancer. The reason for this shift is mainly 
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caused by recent research that indicated the cytotoxic and apoptosis/necrosis-inducing effects of 
certain lectins, combined with the hypothesis that dietary lectins enter the systemic circulation 
intact (Wang et al, 1998). 
 
One important feature appears to be that lectins stimulate the human immune system. Lectins 
were thus reported to exhibit antitumor and anticarcinogenic activities that could be of substantial 
benefit in cancer treatment. Extracts of Viscum album (mistletoe) are widely used as 
complementary cancer therapies in Europe. Mistletoe has been used parenterally for more than 80 
years as an anticancer agent with strong immuno-modulating action. The quality of life of 
patients with late-stage pancreatic cancer was reported to be improved on account of exposure to 
mistletoe lectin (Friess et al, 1996). Immuno-modulation using recombinant ML was reported to 
influence tumor growth in breast cancer patients (Stein et al, 1998). Bladder carcinoma was 
reported to be significantly reduced, and survival times were reported to be prolonged in mice as 
the concentration of ML was increased from 3 to 30 ng. ML increased the life span, decreased the 
tumor growth and decreased hyperplasia of mice and rats with lymphoma and lung cancer 
(Kuttan et al, 1997). 
 
A lectin purified from mesquite seed was reported to have an anti-proliferative effect on the 
cervical human tumor (HeLa) cells and on cell adhesion. Vicia faba agglutinin (VFA), a lectin 
from broad beans was reported to aggregate, stimulate the morphological differentiation of, and 
reduce the malignant phenotype of colon cancer cells (Jordinson et al, 1999). Wheat germ 
agglutinin (WGA) proved to be highly toxic to human pancreatic carcinoma cells in vitro. WGA 
exposure induced chromatin condensation, nuclear fragmentation and DNA release, consistent 
with apoptosis. The binding of the snail lectin Helix pomatia agglutinin (HPA), which recognizes 
N-acetylgalactosamine and N-acetylglucosamine sugars, is considered to be a strong predictor of 
metastasis and unfavorable prognosis in a number of human adenocarcinomas, including breast 
cancer (Brooks and Carter, 2001). Because of their carbohydrate bio-recognition properties, 
lectins may also be used as carriers for targeted drug delivery, in a manner similar to liposomes 
(Wroblewski et al, 2001), provided the possible side effects of such treatments could be 
minimized. 
 
It has been observed that mucosal expression of terminal unsubstituted galactose is increased 
in colon pre-cancerous conditions and cancer, and that it allows interaction with mitogenic 
galactose-binding lectins of dietary or microbial origin. Based on this observation, an interesting 
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hypothesis was postulated whereby galactose might be able to prevent cancer by binding and 
inhibiting such lectins from interacting with colon cancer cells (Evans et al, 2002). D-galactose 
treatment was reported to be effective in liver lectin blocking to prevent hepatic metastases in 
colorectal carcinoma patients (Isenberg et al 1997). Epithelial cancer cells showed an increased 
cell surface expression of mucin antigens with aberrant O-glycosylation, notably Thomsen-
Friedenreich Antigens (TFA). TFA is a carbohydrate antigen with a proven link to malignancy 
(Irazoqui et al 2001). Immunoassays could be utilized for antigens such as TFA in order to 
determine the metastatic potential of breast and colon cancer cells. Molecular changes in the 
membrane surface in the case of both stomach and colon cancer cells occur during the 
progression to carcinogenesis. Carbohydrate patterns displayed on the cellular membrane exterior 
are molecular signatures with unique biological characteristics related to oncogenesis and 
metastasis, and could be used to determine the appropriate chemotherapeutic and surgical 
procedures for each specific cancer. 
 
Lectins have already a demonstrated potential for the treatment, prevention and diagnosis of 
chronic diseases such as cancer. However, further research is required to elucidate the effects of 
purified and dietary lectins and their potential for defense against tumors.  
 
3.  COMPUTATIONAL BIOLOGY, MOLECULAR MODELING AND THEIR 
BIOMEDICAL APPLICATIONS IN NANOMEDICINE 
  
       Computational Biology has a very wide range of applications currently thought of 
‘belonging’ to Biotechnology  (Baianu, 1986) and Bioinformatics (Baianu, 2011),  even though 
the development of such computations has preceded modern Biotechnology by many decades. 
Our approach is to focus on a few selected examples in greater depth, by considering molecular 
modeling techniques that have very wide applications, ranging from ‘pure’ chemistry to 
Biochemistry, Molecular Biology, Biotechnology, Nanomedicine, Pharmacology and  
Pharmacogenomics. 
  
3.1.  Molecular Modeling Techniques   
Molecular modeling is a group of techniques that employ computer-generated images of 
chemical structures that show the relative positioning of all the atoms present in the molecule 
being studied, and/or the simulated dynamics of such molecules together with their ordering 
through space-time.  Such techniques are of considerable help for understanding many 
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physicochemical properties of molecules, and may also provide clues about their possible role(s), 
that is, their function, in the organism. They can be thus especially valuable tools for 
investigating structure-function relationships.  Proteins --within a given protein family-- have, in 
theory, similar sequences and generally share the same basic structure.  Thus, once the structure 
for one member of the protein family is determined, molecular modeling computations can help 
determine the structure for other members of the same protein family.  Such a homology 
technique when applied to protein structure may allow scientists to gain additional insight into 
protein structure, especially for those proteins for which the available experimental data is scarce.   
 
3.1.1 Tasks in Molecular Modeling 
     In order to obtain optimal results, the National Center by Biotechnology (NCBI) suggested that protein 
sequences should be organized in protein families.  Such readily searchable databases (Table 4) are 
currently available for many proteins (NCBI -2003). 
 
 
Table 4. Databases for Molecular modeling 
 
 Protein Data Bank (PDB); 
The molecular modeling database (MMDB) at NCBI 
Clusters of Orthologous Group of proteins (COGs) with the COGNITOR program 
The Basic Local Alignment Search Tool (BLAST) 
Vector Alignment Search Tools (VAST) 
The Conserved Domain Database(CDD) 
Domain Architecture Retrieval Tool (DART). 
 
(Source: NCBI 2003: “A Science primer” ). 
 
 
       Secondly, a target must be selected.  A target is a protein structure that has been determined 
via experiments.   Thirdly, one must generate a purified protein for analysis of the chosen target 
and then determine the protein structure by analytical techniques such as X-ray crystallography 
and/or  2D-FT NMR.  
 
The experiments described next, for example, studied apolipoprotein A-1 by employing 
molecular modeling techniques in order to understand the interaction of proteins in food systems 
and complex organisms.    
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3.1.2. Apolipoprotein Structures 
 
     Lipoprotein in mammals have evolved as the primary transport vehicles for lipids.  This role 
leads to the importance of lipoproteins in several diseases, such as atherosclerosis and 
cardiovascular disease.  Lipoprotein particles consist of a core of neutral lipids, stabilized by a 
surface monolayer of polar lipids complexed with one or more proteins.   
 
     Apolipoprotein A-I and apo B are respectively, the major protein components of high-density 
(HDL) and very low density (VLDL) lipoproteins.  Thus, understanding apolipoproteins is very 
important for medical and health-related fields, such as medical biotechnology, as well as food 
science and human nutrition.    
 
 
3.1.3. Methods of Structure Determination applied to Apolipoprotein Molecules  
  
   The process of biosynthesis, the physical characteristics and the metabolism of apolipoproteins 
have been intensely studied. However, because of the non-crystalline, or paracrystalline structure 
of many apolipoproteins (Baianu, 2012) , it has been difficult to obtain structural data at the 
molecular, or atomic level.   Therefore, methods combining the amino acid sequence with 
molecular methods are now being introduced. Thus, overall structures may be derived from 
correlations of global secondary structures determined from polarized light studies combined 
with local structures predicted from amino acid sequences.  The known amino acid sequence of 
apolipoprotein from the position 7 to 156 of apo Lp-III was first used to design an Apo A-I 
template, that could be then approached by ‘standard’ molecular modeling techniques.    
 
3.1.4.  Molecular Modeling of Apolipoproteins A-I 
 
Target: Apolipoprophorin III is chosen as a target for apolipoprotein A-I.(apo Lp A-I) . 
The structure of Apolipophorin III has been determined in a crystal at 2.5 Å resolution for the 18-
kDa apo Lp III from the African migratory locust, Locusta migratoria and the 22-kDa N-
terminal, receptor-binding domain of human apo E.   
Template for Apo A-I:  Lp IIIa is designed by using molecular software IALIGN from Lp 
III by inserting alanine for template of sequences of apo A-I ( using the program SYBYL, v.5.5).  
Alanine residues are inserted at each of the gap position identified by IALIGN, an interactive 
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alignment program distributed with the Protein Identification Resource (PIR; Eleanor M.B, 
1994)  This model was compared with DgA-I, HuA-I and ChA-I resprsenting canine, human and 
chicken Apo A-I respectively.   Results were then compared using a “strip of  the helix” template 
(Vazquez et al 1992) by scoring 1 or 0 for residues that did , or did not,  fit into the template. 
 
Modeling Results.  
 
A. Sequence Comparison.   The five long α-helices connected by short loops in amino acid 
residues 7-156 of apo Lp-III is used as template for LpIIIa, Dig A-I, DgA-I, HuA-I.  Amphipathic 
potential (AP) is used to detect if the predict structure is suitable for a lipid-aqueous interface in 
its stable condition.  The results are shown in Table 5.   
 
Table 5:  Amphipathic potentials** of predicted helical segments in apolipoprotein models. 
 
Model H1 H2 H3 H4 H5 
 # res AP # res AP # res AP # res AP # res AP 
Lp-III 19 0.79 25 0.8 22 0.77 27 0.7 21 0.67 
Lp-IIIa 19 0.79 25 0.8 24 0.67 33 0.61 22 0.64 
DgA-I 19 0.58 25 0.84 24 0.75 33 0.48 22 0.68 
HuA-I 19 0.53 25 0.88 24 0.71 33 0.45 22 0.73 
ChA-I 19 0.53 25 0.88 24 0.58 33 0.52 22 0.82 
 
 
**Amphipathic potentials (AP) are the best average value for a helical segment of  ( # res)  
residues measured with the “strip of helix”.(Vazquez, et al. 1992) 
 
           B.  Energy minimized models. In this model, electrostatic interactions contributes the most to 
favorable energies.  Alanine was chosen as the spacer residue in building apo Lp-IIIa because of its 
function of small, non-ionic side chain and serves as a helix- stabilizing residue.  Although it has a 
high probability of being found in helical structures, it does not participate through electrostatic 
interactions.  Results of this model are discussed for potential energetic evaluation and amphipathic 
analysis of energy refined helices (see Table 6 and Table 7).  The structure obtained through this 
molecular modeling is illustrated in Figure 6.      
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Figure 6.  Energy Refined models of apo-Lp III and the template apo IIIa constructed by 
inserting alanine residues into gap positions identified when the sequences were aligned with the 
canine, human, and chicken apo A-1 sequences.  Backbone structures for this complete models 
are in panel (a).  The effects of inserted alanine residues on H3, H4, H5 are displayed in panels 
(b), (c), (d) respectively.  In each display, the apo Lp III is shown to the left of the apo Lp-IIIa. 
(SOURCE: Brown et al, 1994). 
 
Table 6.   Energetic evaluation of the refined models   
 Lp-in Lp-lUa DgbjA-I HuA-I ChA-I 
Number of residues 150 165 165 165 165 
Energy, kcal      
Bond stretching 20.7 23.1 28.9 29.2 31.8 
angle bending 123.4 154.0 189.6 208.5 212.2 
torsional 198.1 235.7 308.3 324.6 340.9 
out of plane 26.1 35.8 37.7 41.5 44.5 
1-4 van der Waals 218.7 235.6 247.2 260.2 270.3 
van der Waals -993.0 -1094.3 -1074.8 -1131.8 -1155.6 
1-4 electrostatics 1684.0 1813.3 1497.1 1566.7 1524.1 
electrostatic -4497.8 -4567.3 -5214.7 -5182.6 -5208.4 
H-bond -69.3 -70.2 -64.5 -69.8 -76.3 
Total Energy, kcal -3289.0 -3234.3 -4045.2 -3953.6 -4016.4 
kcal/mol/residue -21.9 -19.6 -24.5 -24.0 -24.3 
H1 (residues) (7-25)  (72-90) (73-88) (72-90) 
kcal/mol/residue -16.1  -18.5 -16.6 -17.4 
H2 (residues) (35-59)  (100-124) (101-125) (100-124) 
kcal/mol/residue -16.1  -20.1 -19.4 -19.2 
H3 (residues) (70-91) (70-91) (135-158) (136-159) (135-158) 
kcal/mol/residue -17.6 -20.7 -18.4 -16.2 -17.6 
H4 (residues) (96-121) (96-121) (166-196) (167-197) (166-196) 
kcal/mol/residue -15.5 -13.8 -16.7 -16.9 -17.6 
H5 (residues) (136-155) (136-155) (207-235) (208-236) (207-235) 
kcal/mol/residue -15.8 -15.4 -14.0 -13.4 -14.9 
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These energy calculations, based on the sequence segments initially assigned to HI -H5 (see  
Tables 6 and 7), are given to illustrate the stability of the structures. Sequences for helices 3 to 
5  (H3, H4, H5) of apo Lp-IIIa contain inserted alanine residues. (Source: Brown, 1994). 
Table 7.  Amphipathic analysis of energy refined helices 
Model Lp-III Lp-IIIa gA-I HuA-I ChA-I 
HI N7-E25 N7-E25 D72-E90 D73-K88 E72-E90 
Hb sector 140° 140° 100° 60° 100° 
Av. Hb 0.98 0.98 0.78 0.7 0.81 
H2 P35-S59 P35-S59 L100-E124 L101-E125 L101-E124 
Hb sector 100° 100° 100° 100° 100° 
Av. Hb 0.8 0.8 0.7 0.89 0.95 
H3 S70-T91 S70-S85 Q137-R150 E136-R149 L135-L151 
Hb sector 140° 120° 100° 100° 120° 
Av. Hb 0.93 0.79 0.95 0.88 0.82 
H4      
H4A A96-S121 Q98-T107 D168-K181 Q172-E179 D167-R181 
Hb sector 100° 140° 80° 100° 80° 
Av. Hb 0.56 0.91 1.1 0.94 1.18 
H4B  Q117-al21d S187-S196 A190-A194 P186-V195 
Hb sector  60° 100°  60° 
Av. Hb  0.45 0.45  0.66 
H5 E136-V156 L134-A155 L213-I232 L214-T237 E212-L235 
Hb sector 120° 80° 100° 100° 100° 
Av. Hb 0.74 0.53 1.05 0.96 0.86 
 
\ 
Table 7.  The size of the hydrophobic (Hb) sector of a helix was determined from helical 
Wheel projections (Schiffer et al 1967) The average hydrophobicity (Av. Hb), of this  
sector was calculated by the method of Eisenberg (1984) . Single letter designations are  
used for Amino acid residues, (al21d) designates the fourth alanine residue inserted  
between residues 121 and 122 of Lp-III. (Source: Brown, 1994). 
 
 
After evaluating the potential energy for this model, the lateral view structures of apolipoproteins 
for apo lipophorin III(residues 7-156), canine apolipoptrotein A-I (residues 72-236), human 
apolipoprotein A-I (residues 73-237) and chicken apolipoprotein A-I (residues 72-236).  
The computation results are shown in Figure 7  (according to Brown, 1994). 
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Figure 7. Energy refined models of from left to right apo lipophorin III(residues 7-156) canine 
apolipoptrotein A-I (residues 72-236), human apolipoprotein A-I (residues 73-237) and chicken 
apolipoprotein A-I (residues 72-236).  Peptide backbones are represented by a double stranded 
ribbon.  In the lateral view, only ionizable sidechains are displayed with acidic groups in red and 
basic groups in blue.  In the end-on view of the molecules only the hydrophobic sidechains are 
displayed in orange. (Source: Brown, 1994) 
 
 
3.2. Combination of Molecular Modeling with Other Techniques 
 
It is important to combine molecular modeling with other techniques in order to improve the 
accuracy of the modeling results.  A recent study of Apolipoprotein has produced a high-
resolution reconstruction of the structure of apolipoprotein through combination with a solution-
phase X-ray technique. It was shown that Apoliproprotein A-1 is an 243-residue protein that 
contains a globular amino-terminal domain (residue 1-43) and a lipid-binding carboxyl-terminal 
domain (residues 44-243; Segrest et al, 1992).  The aqueous phase X-ray diffraction crystal 
structure was obtained at 4 Å (0.4 nm) resolution, which is moderate.  This has suggested the 
accuracy of molecular modeling by combining the X-ray crystallographic with molecular 
modeling (Figure 8; from Segrest et al, 1992.; Borhani, 1997). 
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Figure 8. X-ray Diffraction Crystal structure of the Apolipoprotein A-I: Δ( 1-43) dimer in 
solution. (Source:  Borhani et al.  1997). 
 
 
 
3.3. In-Depth Analyses of Molecular Structure 
 
        The determination of apolipoprotein A-I can be then further associated with lipid containing 
domains by employing other molecular modeling techniques, such as VMD (generated in The 
Beckman Research Institute at the University of Illinois at Urbana, IL, USA) . The ‘belt model’ is 
used to show the possible orientations of lipoprotein with its apolipoprotein inserted                 
(Figure 9). The suggested structure can then serve as a template in other high density 
lipoproteins for their structure determination and also help in understanding the biological 
interaction.  
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3.4. Practical Applications of Molecular Modeling 
Molecular modeling has been introduced for more than two decades ago.  Increasingly, 
modeling software is available for a variety of industrial applications.  Global markets for 
molecular modeling, in general, currently exceed 2 billion US $ annually (Fuji-Keizai, 2003). 
 
3.4.1. Examples of Medical Applications of Molecular Modeling  
      Molecular modeling is especially helpful in the medical/biomedical and pharmacological 
fields, such as in nanoscale development of novel drugs of increased potency. Recent studies 
have shown the importance of using molecular modeling in medical, food sciences and nutrition 
(Food Ingredient first, 2003).  The molecular modeling of Epigallocatechin Gallate (EGCG), and 
the HIV cell was undertaken by Shearer (2003).  His report has inspired scientists in Japan who 
discovered the potential of green tea as an anti-HIV drug.  The chemical compound that is found 
abundantly in the green tea called Epigallocatechin Gallate (EGCG) is reported to stop the HIV 
virus from binding to CD4 molecules and human T-cells.  
 
3.4.2. Other Applications of Molecular Modeling 
    Other applications of molecular modeling to pharmacology, manufacturing, life sciences and 
chemistry greatly benefit from such molecular modeling programs.  Nanotechnology has 
developed to a 30 to 40 million US $ market, and it also has the potential to grow to a 60 to 70 
million US $ market within the next five years (Fuji-Keizai, 2003). 
 
 
Fig 9a.  Detailed Belt model displayed as 
a helical ribbon.  C(NH2)3, blue, oxygen 
atom, red; phosphorous atom, yellow all 
other atom, black.  
( Source: Borhani 1997)   
Fig 9b.  Detailed Belt model displayed as 
all atom model, oriented in 9a.  nitrogen 
atom, blue, oxygen atom, red; carbon 
atom, cyan, polar hydrogen atom, white. ( 
Source: Borhani 1997)   
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4. CONCLUSIONS  
A summary and simplified overview of the selected applications of nanotechnology in the 
areas of Nanomedicine, foods, human nutrition and health- as well as the potential large-scale 
applications in the chemical industry- that were discussed in this report is presented in Table 8.   
 
Table 8. Selected Biotechnology and Nanotechnology Tools and Their Applications 
NOVEL TECHNIQUES AREA APPLICATION 
Brewing industry 
Dairy Foods
Neutraceuticals
Regulation of fibrinolisis
Detoxification of water
Synthesis of complex carbohydrates
cloning of cellulose degrading enzyme
Addition of vitamins  in foods 
Reduction of ripening 
Bioproduction of fuel
Flavor delivery 
Additives in bakery
Chesee ripening
protecion of DNA interactions 
Gene therapy 
Vaccines
Drug carrier against Cancer and HIV  
Creams 
Oil spills separations 
Food Applications 
Medical applications
Other 
Liposomes in Microencapsulation 
Food Applications 
Human Nutrition
Other 
Genetic Manipulation 
Medical applications
Food Applications 
Immobilized cells 
Human Nutition
Medical Applications 
 
The rapid development of biotechnological tools and ‘quick’ applications oriented 
towards immediate marketing may be responsible for generating legislative barriers against 
‘GMO-based’ products. The complementary area of genetically manipulated microorganisms is 
adopting novel approaches to overcome such increasingly unprofitable legislative barriers and 
boost profits both in the short- and long-term.  
The use of ultra-sensitive techniques and biocomputational modeling is essential in order 
to quantitate the physical and chemical properties of molecules and supra-molecular systems that 
are of primary interest to developments in nanotechnology and its applications to Nanomedicine.  
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Policy changes may be therefore considered and implemented that would take advantage of such 
novel approaches to develop new niches and markets for both profitable and safe 
Nanotechnology applications worldwide, in the Chemical Industry, Agriculture, Health and 
Medicine. 
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